IGC Announces Phytocannabinoid Focused Pharmaceutical Unit

IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in itseffort to gain a leading position in the emerging legal cannabisindustry.  Our strategy is to develop a product portfolio ofphytocannabinoid-based therapies for the treatment of a wide rangeof therapeutic indications including pain, epilepsy, and otherniche severe terminal diagnosis, which are life altering or lifethreatening.   Most recently, the company applied for a provisional patentbased on a novel therapy that uses cannabinoid extracts for thetreatment of seizures in dogs and cats. The therapy, which isexpected to also have applications in humans, is administered usinga variety of delivery technologies. We expect to establishmetabolic profiling and apply to the FDA for trials.To facilitate the development of the product portfolio, IGC isentering into partnerships with a range of organizations that canprovide cost effective solutions for metabolic profiling, clinicaltrials, and regulatory approvals that in most cases will benecessary to eventually commercialize our products."The Company is also continuing to assemble an internationalnetwork of doctors, veterinarians, and researchers with extensiveexpertise in various indications, medicines containing controlledsubstances, plant-based products, extraction technologies, and drugdelivery technologies.  In addition, we have assembled expertsin patent law, clinical trials, and regulatory procedures," saidRam Mukunda, IGC's CEO.Mukunda added, See full press release